The company delivers clinician-supervised sublingual and subcutaneous ketamine as part of a comprehensive therapeutic program, rather than operating as a prescription-only service. Mindbloom's integration framework (journaling prompts, recorded playlists, guided sessions) is the most polished in the industry. In a peer-reviewed study of 11,441 Mindbloom clients, 89% of participants reported improvement in their symptoms, with 56.4% meeting criteria for depression response and 56.1% meeting criteria for anxiety response.
Cyborg Score Rationale
Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy to date, both published in the Journal of Affective Disorders. The company operates at scale with over 700,000 sessions and achieves differentiation through comprehensive clinical support and proprietary administration methods. However, the regulatory status of compounded ketamine and recent legal challenges (June 2025 defamation lawsuit and October 2025 wrongful-death lawsuit) create strategic headwinds.
Top Insights
Mindbloom is the only at-home ketamine provider offering subcutaneous administration, which enables more consistent dosing than oral ketamine or sublingual tablets.
In September 2019, Mindbloom became an exclusively virtual business, then opened an in-person clinic on New York's Fifth Avenue in March 2020, described as the city's first legal, upscale guided psychedelic therapy center.
In June 2025, Mindbloom filed a defamation lawsuit against the publisher of The Wall Street Journal, alleging a 2024 article falsely implied Mindbloom's connection to actor Matthew Perry's death, though Perry had never been a client.
Mindbloom offers at-home ketamine therapy for 75% less than in-person clinics.
Named Competitors
Joyous — At-home ketamine therapy via daily microdosing subscription model
Nue Life — At-home guided ketamine therapy provider
IV Ketamine Clinics — In-person intravenous ketamine therapy ($400-$1,000+ per infusion)
Recent Developments
(June 2025) Filed defamation lawsuit against Dow Jones & Company regarding Matthew Perry article
(October 2025) Faced wrongful-death lawsuit in North Carolina alleging inadequate patient screening
(March 2026) Published PTSD outcomes study showing 92.2% reported symptom improvement among 374 program completers
(May 2026) Maintained market position as leading at-home ketamine provider with published clinical evidence
Open the full interactive Mindbloom report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.